menu

MYR Pharmaceuticals — Treatment of HBV & HDV Infections

Career opportunities — Join our team! Privacy Policy

First-in-class entry inhibitor in the field of Hepatitis D

Bulevirtide

MYR Pharmaceuticals is focused on the development of Bulevirtide (formally known as Myrcludex B), a first-in-class entry inhibitor for treatment of chronic hepatitis B and D infections. We started our operations in 2011. Our technology was originally developed at the University of Heidelberg (Germany) and INSERM (France) and represents one the most clinically advanced novel approaches for treatment of hepatitis B and D.

Our mission

Bring true benefit to patients suffering from chronic Hepatitis D

Around 15-20 million people develop chronic hepatitis D virus worldwide. A vaccine against hepatitis B is today the only method to prevent HDV infection. At MYR Group we fully dedicate our work to bring benefit to Hepatitis D patients targeting a disease with high unmet medical need.

News

May 29, 2020 – Positive CHMP opinion for HEPCLUDEX®

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for HEPCLUDEX® (Bulevirtide, formerly known as Myrcludex B), the First-in-Class Entry Inhibitor for the treatment of chronic hepatitis D infections.

features

MYR Pharmaceuticals is a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis B (HBV)  and D (HDV) infections. The company’s lead compound Bulevirtide (formerly known as Myrcludex B) is a first-in-class entry inhibitor for treatment of chronic HBV and HDV and is currently in a Phase 3 study in the indication of chronic HDV.

We are proud that our medicine has received:

If you want to collaborate with MYR Pharmaceuticals please contact

In addition to the license agreement, MYR has a collaboration and research agreement with the University Hospital Heidelberg!

our investors and partners